COSMO Pharmaceuticals SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares COSMO Pharmaceuticals SA with three other
pharmaceutical manufacturers in Europe:
Cathay International Holdings Ltd
of the United Kingdom
sales of £63.36 million [US$79.20 million]
Mithra Pharmaceuticals SA
(57.88 million Euro [US$64.09 million]
of which 97%
was Out-licensing), and
based in Sweden
(783.10 million Swedish Kronor [US$80.97 million]
of which 79%
COSMO Pharmaceuticals SA reported sales of 65.62 million Euro (US$72.67 million)
December of 2018.
decrease of 2.4%
versus 2017, when the company's sales were 67.24 million Euro.
Contributing to the drop in overall sales was the 24.2% decline
in Manufacturing of Mmx Products, from 36.32 million Euro to 27.52 million Euro.
There were also decreases in sales in
Manufacturing of Generic Products and Sp (down 5.9% to 7.78 million Euro)
Royalties (down 19.0% to 14.64 million Euro)
However, these declines were partially offset by the increase in sales of
Marketed Products Eleview (up 331.1% to 6.76 million Euro)
License Fees and Milestones (up 280.3% to 5.71 million Euro)
Related Services (up 215.8% to 2.28 million Euro)
Other Revenues From Sale (up 17.4% to 945,000.00 Euro)